Mortality benefit from unrestricted access to clopidogrel: too good to be true?
Suissa
Samy
S
Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre and the Department of Epidemiology and Biostatistics, McGill University, Montréal, Que. samy.suissa@clinepi.mcgill.ca
D015906:Angioplasty, Balloon, Coronary; D002170:Canada / Q000453:epidemiology; D000077144:Clopidogrel; D023903:Coronary Restenosis / Q000401:mortality* / Q000517:prevention & control*; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D006297:Health Services Accessibility / Q000639:trends*; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine